<DOC>
	<DOCNO>NCT01168713</DOCNO>
	<brief_summary>Study evaluate safety efficacy oral CEM-101 compare oral Levofloxacin treatment adult moderate moderately severe community-acquired bacterial pneumonia .</brief_summary>
	<brief_title>Efficacy Safety Study Oral CEM-101 Compared Oral Levofloxacin Treatment Patients With Community-Acquired Bacterial Pneumonia</brief_title>
	<detailed_description>Community-acquired bacterial pneumonia acute infection pulmonary parenchyma symptom fever hypothermia , chill , rigor , chest pain , and/or dyspnea . The widespread emergence antibiotic resistant pathogen , include macrolide-resistant Streptococcus pneumoniae , result need new effective antibiotic activity CABP pathogens . CEM-101 first fluoroketolide excellent vitro vivo activity resistant S. pneumoniae key typical atypical bacterial respiratory pathogen .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>1 . Diagnosis community acquire bacterial pneumonia ( e.g . cough purulent sputum change character sputum consistent bacterial infection , dyspnea tachypnea , chest pain due pneumonia , fever , presence rale and/or sign consolidation ) . 2 . No prior systemic antibacterial therapy , unless fail therapy . 3 . Chest Xray show new lobar multilobar infiltrate ( ) consistent acute bacterial pneumonia . 4 . PORT Risk Class II , III , IV &lt; =105 5 . Ability take oral medication . 1 . Severe chronic obstructive pulmonary disease FEV1 &lt; 30 % . 2 . Hospitalization within 90 day residence longtermcare facility within 30 day prior onset symptom 3 . Chemotherapy radiation therapy within previous 3 month . 4 . Significant hepatic , hematological , renal abnormality . 5 . Any concomitant condition , opinion Investigator , would preclude evaluation response make unlikely contemplated course therapy followup could complete ( e.g . life expectancy &lt; 30 day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adults Community-Acquired Bacterial Pneumonia</keyword>
</DOC>